Ftse Mib
34.938,90
0,45%
DAX
20.340,57
0,65%
S&P 500
5.909,03
-1,11%
NASDAQ
19.489,68
-1,89%
Bitcoin
96.169,35
-0,76%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Celularity Inc (CELU) Celularity Inc (CELU) Notizie

Celularity Inc

CELU
2,34
0,08 (3,54%)
07 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/12/202414:00GLOBECelularity Inc. Announces Resolution of Nasdaq Listing..
06/12/202414:00GLOBECelularity Reports Over Sevenfold Growth in Net Product..
27/11/202423:00GLOBECelularity Inc. Announces Receipt of Nasdaq Notification
20/11/202414:30GLOBECelularity’s Strategic Partner Announces Groundbreaking for..
18/11/202414:30GLOBECelularity Inc. Announces Resolution of Nasdaq Listing..
07/11/202414:00GLOBECelularity Raises Full Year 2024 Guidance as Expected Net..
23/10/202414:30GLOBECelularity Files Appeal Request and Amended Compliance Plan..
22/10/202414:30GLOBECelularity Provides Corporate Update
19/10/202400:00GLOBECelularity Inc. Receives Notice from Nasdaq; Confirms..
16/10/202423:15GLOBECelularity Expands Advanced Biomaterial Product Commercial..
05/9/202422:05GLOBECelularity to Present at H.C. Wainwright’s 26th Annual..
28/8/202423:23EDGAR2Form 8-K - Current report
28/8/202422:45GLOBECelularity Appoints Richard J. Berman to its Board of..
23/8/202423:15EDGAR2Form 8-K - Current report
23/8/202423:00GLOBECelularity Inc. Announces Receipt of Nasdaq Notice Regarding..
16/8/202422:45EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
05/8/202423:15EDGAR2Form 8-K - Current report
31/7/202414:30GLOBECelularity Reports Full Year 2023 Combined Net Sales of..
30/7/202422:26EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
03/6/202414:38GLOBECelularity Presents Data of The Effect of Its T-Cell..
24/5/202423:15GLOBECelularity Inc. Announces Receipt of Nasdaq Notice Regarding..
14/5/202415:15GLOBECelularity Data Published in Journal for ImmunoTherapy of..
22/4/202414:00GLOBECelularity Inc. to Host Investor and Analyst Research &..
19/4/202423:30GLOBECelularity Inc. Announces Receipt of Nasdaq Notice Regarding..
18/4/202422:30GLOBECelularity Abstract “Emerging Technologies for the..
15/4/202414:00GLOBECelularity Announces Net Sales Trending Ahead of..
08/4/202415:00GLOBECelularity to Present Data Showing Senescent Cell..
26/3/202414:00GLOBECelularity Receives Healthcare Common Procedure Coding..
20/3/202414:15GLOBECelularity Submits Request to U.S. FDA for Orphan Drug..
14/3/202414:15GLOBECelularity CEO to Present on Cell Therapy’s Potential to..
12/3/202414:20GLOBECelularity CEO to Present Keynote Address at 2024 Society..
07/3/202415:35GLOBECelularity to Present Data Showing Cancer Tumor Reduction by..
26/2/202423:15EDGAR2Form 8-K - Current report
23/2/202422:10GLOBECelularity Announces 1-for-10 Reverse Stock Split
22/2/202415:05EDGAR2Form 8-K - Current report
22/2/202403:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:05GLOBECelularity’s Tri-layer Decellularized, Dehydrated Human..
12/2/202422:15EDGAR2Form 8-K - Current report
02/2/202412:01EDGAR2Form DEF 14A - Other definitive proxy statements
01/2/202415:00GLOBECelularity Announces Net Sales Expectations for First..
25/1/202415:00GLOBECelularity and Genting Leaders Comments on Closing $21..
23/1/202412:02EDGAR2Form PRE 14A - Other preliminary proxy statements
18/1/202419:40GLOBECelularity Releases CEO Letter to Shareholders
17/1/202423:15EDGAR2Form SC 13D/A - General statement of acquisition of..
17/1/202422:14EDGAR2Form 8-K - Current report
09/1/202422:49EDGAR2Form 8-K - Current report
Apertura: 2,27 Min: 2,20 Max: 2,3402
Chiusura: 2,26

La tua Cronologia

NASDAQ
CELU
Celularity
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network